Research programme: norovirus and rotavirus vaccine - University of Tampere/UMN Pharma

Drug Profile

Research programme: norovirus and rotavirus vaccine - University of Tampere/UMN Pharma

Alternative Names: UMN-103; UMN-104; UMN-2001; UMN-2002; UMN-2003

Latest Information Update: 27 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Tampere Vaccine Research Center
  • Developer UMN Pharma; University of Tampere Vaccine Research Center
  • Class Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gastroenteritis; Norovirus infections; Rotavirus infections

Most Recent Events

  • 31 Oct 2017 UMN Pharma terminates its research agreement with Daiichi Sankyo Company concerning its Norovirus VLP vaccine, UMN 2002
  • 10 Oct 2016 norovirus and rotavirus vaccine are still in preclinical development in Rotavirus-infections, Gastroenteritis and Norovirus-infections (In children, Prevention) in Finland (Parenteral, Injection) (UMN Pharma pipeline, October 2016)
  • 10 Oct 2016 UMN Pharma plans a phase I/II trial for UMN 2003 for acute Gastroenteritis in Finland (UMN Pharma pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top